{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T05:13:02Z","timestamp":1786597982269,"version":"build-2736575974"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303511"],"award-info":[{"award-number":["82303511"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Project of Hunan Provincial Health Commission","award":["B202304017222"],"award-info":[{"award-number":["B202304017222"]}]},{"name":"Hunan Provincial People\u2019s Hospital RenShu fund","award":["RS2022A07"],"award-info":[{"award-number":["RS2022A07"]}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation of China","doi-asserted-by":"crossref","award":["2024JJ7479, 2025JJ80711"],"award-info":[{"award-number":["2024JJ7479, 2025JJ80711"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Hunan Provincial Key Laboratory of Prevention and Treatment of Biliary Tract Diseases","award":["2023TP1045"],"award-info":[{"award-number":["2023TP1045"]}]},{"name":"Hunan Province Innovation Guidance Project","award":["2020SK50913"],"award-info":[{"award-number":["2020SK50913"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Objectives<\/jats:title>\n                  <jats:p>The prognosis of biliary tract cancers (BTC) after radical resection is still unsatisfactory. However, the clinical value of adjuvant therapy remains controversial. This retrospective study aimed to evaluate the clinical value of adjuvant chemotherapy and adjuvant chemoimmunotherapy in patients with BTC after radical resection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data from BTC patients who underwent radical resection were retrospectively obtained from Hunan Provincial People\u2019s Hospital between January 2020 and July 2024. Patients were divided into observation group, adjuvant chemotherapy group, and adjuvant chemoimmunotherapy group according to the treatment received by the patient after surgery. Survival curves were determined by the Kaplan\u2013Meier method. The COX proportional hazards regression model was used to determine independent prognostic risk factors. The adjuvant chemotherapy group and adjuvant chemoimmunotherapy group were analyzed by PSM at a 1:1 ratio.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 219 patients with BTC were reenrolled in this study, with 108 cases of iCCA, 39 cases of pCCA, 15 cases of DCCA, and 57 cases of GBC. Eighty-seven patients (39.73%) received surgery alone, 69 patients (31.51%) received postoperative adjuvant chemotherapy, and 63 patients (28.77%) received postoperative adjuvant chemoimmunotherapy. There was no different significance for median recurrence-free survival (RFS) in the 3 groups (13.20 vs 20.40 vs 19.68 months; P\u2005=\u2005.195). The median overall survival (OS) was the longest in the chemoimmunotherapy group (29.20 vs 31.5 vs 43.27 months; P\u2005=\u2005.003). After propensity score matching (PSM), there was no difference in median RFS in the 2 adjuvant groups (22.03 vs 19.87 months; P\u2005=\u2005.350). The median OS was longer in the chemoimmunotherapy group (45.27 vs 29.40 months; P\u2005=\u2005.015). In Cox analysis, lymph node metastasis, differentiation, and adjuvant treatment were the independent predictors of OS in patients with BTC. The most common adverse events were of any grade of hematologic toxicity. No drug-related deaths occurred in either group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The safety of chemoimmunotherapy was acceptable and could significantly prolong the overall survival of BTC. These data provided a basis for an additional prospective clinical trial to evaluate the efficacy of chemoimmunotherapy in adjuvant therapy for BTC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf163","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T07:28:18Z","timestamp":1748849298000},"source":"Crossref","is-referenced-by-count":4,"title":["Postoperative adjuvant chemotherapy and chemoimmunotherapy after radical resection for biliary tract cancer: a retrospective study"],"prefix":"10.1093","volume":"30","author":[{"given":"Yuhuai","family":"Peng","sequence":"first","affiliation":[{"name":"Central Laboratory, Hunan Provincial People\u2019s Hospital\/The First Affiliated Hospital of Hunan Normal University , Changsha,","place":["P. R. China"]},{"name":"Department of Hepatobiliary Surgery, Hunan Provincial People\u2019s Hospital\/The First Affiliated Hospital of Hunan Normal University , Changsha,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyi","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, The Central Hospital of Shaoyang , Shaoyang,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Hunan Provincial People\u2019s Hospital\/The First Affiliated Hospital of Hunan Normal University , Changsha,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Hunan Provincial People\u2019s Hospital\/The First Affiliated Hospital of Hunan Normal University , Changsha,","place":["P. R. China"]},{"name":"The First school of Clinical Medicine, Lanzhou University , Lanzhou,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulai","family":"Liu","sequence":"additional","affiliation":[{"name":"Central Laboratory, Hunan Provincial People\u2019s Hospital\/The First Affiliated Hospital of Hunan Normal University , Changsha,","place":["P. R. China"]},{"name":"Department of Hepatobiliary Surgery, Hunan Provincial People\u2019s Hospital\/The First Affiliated Hospital of Hunan Normal University , Changsha,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Hunan Provincial People\u2019s Hospital\/The First Affiliated Hospital of Hunan Normal University , Changsha,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuewei","family":"Tao","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Dundee, Ninewells Hospital , Dundee,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, Hunan Provincial People\u2019s Hospital\/The First Affiliated Hospital of Hunan Normal University , Changsha,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6592-6678","authenticated-orcid":false,"given":"Yinghui","family":"Song","sequence":"additional","affiliation":[{"name":"Central Laboratory, Hunan Provincial People\u2019s Hospital\/The First Affiliated Hospital of Hunan Normal University , Changsha,","place":["P. R. China"]},{"name":"Department of Hepatobiliary Surgery, Hunan Provincial People\u2019s Hospital\/The First Affiliated Hospital of Hunan Normal University , Changsha,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"key":"2025062705234554800_CIT0001","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"2025062705234554800_CIT0002","doi-asserted-by":"publisher","first-page":"694","DOI":"10.6004\/jnccn.2023.0035","article-title":"NCCN Guidelines\u00ae Insights: Biliary Tract Cancers, version 2.2023","volume":"21","author":"Benson","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"2025062705234554800_CIT0003","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"2025062705234554800_CIT0004","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jamcollsurg.2016.05.019","article-title":"Recurrence patterns and disease-free survival after resection of intrahepatic cholangiocarcinoma: preoperative and postoperative prognostic models","volume":"223","author":"Doussot","year":"2016","journal-title":"J Am Coll Surg"},{"key":"2025062705234554800_CIT0005","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S1470-2045(24)00082-2","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Burris","year":"2024","journal-title":"Lancet Oncol"},{"key":"2025062705234554800_CIT0006","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025062705234554800_CIT0007","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","article-title":"Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"401","author":"Nakachi","year":"2023","journal-title":"Lancet"},{"key":"2025062705234554800_CIT0008","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1002\/cam4.2925","article-title":"Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma: a multicenter retrospective study","volume":"9","author":"Wang","year":"2020","journal-title":"Cancer Med"},{"key":"2025062705234554800_CIT0009","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1186\/s12885-022-10269-0","article-title":"Efficacy and safety of adjuvant chemotherapy in T1N0M0 intrahepatic cholangiocarcinoma after radical resection","volume":"22","author":"Li","year":"2022","journal-title":"BMC Cancer"},{"key":"2025062705234554800_CIT0010","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1097\/HEP.0000000000000046","article-title":"Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial","volume":"77","author":"Jeong","year":"2023","journal-title":"Hepatology"},{"key":"2025062705234554800_CIT0011","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/17474124.2021.1853527","article-title":"Recent advances of immunotherapy for biliary tract cancer","volume":"15","author":"Rizzo","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2025062705234554800_CIT0012","doi-asserted-by":"publisher","first-page":"1109292","DOI":"10.3389\/fimmu.2023.1109292","article-title":"Efficacy and safety of lenvatinib combined with PD-1\/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Immunol"},{"key":"2025062705234554800_CIT0013","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3892\/etm.2023.12051","article-title":"Efficacy and safety of PD-1 inhibitor plus antiangiogenic treatment in patients with unresectable biliary tract cancer: a multicenter retrospective study","volume":"26","author":"Wu","year":"2023","journal-title":"Exp Ther Med"},{"key":"2025062705234554800_CIT0014","doi-asserted-by":"publisher","first-page":"21742","DOI":"10.1002\/cam4.6738","article-title":"Adjuvant chemotherapy combined with immunotherapy in patients with cholangiocarcinoma after radical resection","volume":"12","author":"Li","year":"2023","journal-title":"Cancer Med"},{"key":"2025062705234554800_CIT0015","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1097\/JS9.0000000000002161","article-title":"The efficacy of adjuvant chemotherapy for curative resected biliary tract cancers: a systematic review and network meta-analysis of randomized clinical trials","volume":"111","author":"Peng","year":"2025","journal-title":"Int J Surg"},{"key":"2025062705234554800_CIT0016","doi-asserted-by":"publisher","first-page":"81394","DOI":"10.18632\/oncotarget.19037","article-title":"DCK expression, a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection: results from a phase II study","volume":"8","author":"Woo","year":"2017","journal-title":"Oncotarget"},{"key":"2025062705234554800_CIT0017","doi-asserted-by":"publisher","first-page":"101788","DOI":"10.1016\/j.clinre.2021.101788","article-title":"The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: a systematic review and meta-analysis","volume":"46","author":"Song","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2025062705234554800_CIT0018","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s10147-018-1283-6","article-title":"Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer","volume":"23","author":"Nakachi","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"2025062705234554800_CIT0019","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"Int J Cancer"},{"key":"2025062705234554800_CIT0020","doi-asserted-by":"publisher","first-page":"17588359241235799","DOI":"10.1177\/17588359241235799","article-title":"Immunotherapy for the treatment of biliary tract cancer: an evolving landscape","volume":"16","author":"Wilbur","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"2025062705234554800_CIT0021","doi-asserted-by":"publisher","first-page":"744571","DOI":"10.3389\/fimmu.2021.744571","article-title":"Successful treatment of advanced intrahepatic cholangiocarcinoma with a high tumor mutational burden and PD-L1 expression by PD-1 blockade combined with tyrosine kinase inhibitors: a case report","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"2025062705234554800_CIT0022","doi-asserted-by":"publisher","first-page":"11795549251317012","DOI":"10.1177\/11795549251317012","article-title":"Comparing immunotherapy versus chemotherapy alone as second-line therapy for malignant tumors of the biliary tract: a retrospective study","volume":"19","author":"Jiang","year":"2025","journal-title":"Clin Med Insights Oncol"},{"key":"2025062705234554800_CIT0023","doi-asserted-by":"publisher","first-page":"74","DOI":"10.7150\/jca.16774","article-title":"Activation or suppression of the immune response mediators in biliary tract cancer (BTC) patients: a systematic review and meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"J Cancer"},{"key":"2025062705234554800_CIT0024","doi-asserted-by":"publisher","first-page":"114000","DOI":"10.1016\/j.ejca.2024.114000","article-title":"Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)","volume":"202","author":"Roth","year":"2024","journal-title":"Eur J Cancer"},{"key":"2025062705234554800_CIT0025","doi-asserted-by":"publisher","first-page":"e0664","DOI":"10.1097\/HC9.0000000000000664","article-title":"IL-8-NF-\u03baB-ALDH1A1 loop promotes the progression of intrahepatic cholangiocarcinoma","volume":"9","author":"Song","year":"2025","journal-title":"Hepatol Commun"},{"key":"2025062705234554800_CIT0026","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1148\/radiol.2018181408","article-title":"Biliary tract cancer at CT: a radiomics-based model to predict lymph node metastasis and survival outcomes","volume":"290","author":"Ji","year":"2019","journal-title":"Radiology"},{"key":"2025062705234554800_CIT0027","doi-asserted-by":"publisher","first-page":"893509","DOI":"10.3389\/fonc.2022.893509","article-title":"Recommendations of the clinical target volume for the para-aortic region based on the patterns of lymph node metastasis in patients with biliary tract cancer","volume":"12","author":"Long","year":"2022","journal-title":"Front Oncol"},{"key":"2025062705234554800_CIT0028","doi-asserted-by":"publisher","first-page":"e1051","DOI":"10.1093\/oncolo\/oyae076","article-title":"EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance","volume":"29","author":"Kim","year":"2024","journal-title":"Oncologist"},{"key":"2025062705234554800_CIT0029","doi-asserted-by":"publisher","first-page":"21548","DOI":"10.1038\/s41598-023-48889-6","article-title":"Development of a nomogram to predict survival in advanced biliary tract cancer","volume":"13","author":"Imaoka","year":"2023","journal-title":"Sci Rep"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf163\/63415059\/oyaf163.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/6\/oyaf163\/63415059\/oyaf163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/6\/oyaf163\/63415059\/oyaf163.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T09:23:55Z","timestamp":1751016235000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf163\/8154833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf163","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,6]]},"article-number":"oyaf163"}}